CBP-501 

CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser²¹⁶-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC₅₀ values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer^[1][2].

CBP501 enhances cytotoxicity of CDDP and Bleomycin against cancer cells both in vitro and in vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1929.06

C₈₆H₁₂₂F₅N₂₉O₁₇

565434-85-7

Solid

White to off-white

d({4-Bz-Phe}-Ser-Trp-Ser-{pentafluoro-Phe}-{Cha}-Arg-Arg-Arg-Gln-Arg-Arg)

d({4-Bz-Phe}-SWS-{pentafluoro-Phe}-{Cha}-RRRQRR)

Room temperature in continental US; may vary elsewhere.

• [1]. Enzler T, et al. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. Eur J Cancer. 2024 Apr;201:113950.  [Content Brief]

  [2]. Shi-Ken Sha, et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther. 2007 Jan;6(1):147-53.  [Content Brief]